Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Androgenetic Alopecia (AGA)
- Main trialPhase 1/2
- “This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.”In the company’s words, NCT07327359 on ClinicalTrials.gov
Other drugs for Androgenetic Alopecia (AGA)
- RitlecitinibPfizer · Phase 3
- VDPHL01Veradermics, Inc. · Phase 3
- OMA102EMS · Phase 3
- DA-001Applied Biology, Inc. · Phase 2/3
- DeuruxolitinibSun Pharma · Phase 3
- CKD-843Chong Kun Dang Pharmaceutical · Phase 3
Coming up1
- Sep 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Sep 2027 | A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026